title: [Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
abstract: The application of levodopa/carbidopa intestinal gel (LCIG), which provides the more reliable control of the disease and decrease in progression rates compared to standard treatment, is a variant of treatment of severe forms of Parkinson's disease. An analysis of pharmacoeconomic aspects of LCIG use in foreign countries has shown that this treatment significantly improves expectancy of patients and reduces the costs of professional care. The approximate threshold values of costs per 1 QALY recommended for reimbursement of intervention costs are £30,000 in the United Kingdom and €50,000 in Sweden. In respect to intervention, LCIG can be regarded as an acceptable drug.
authors.forename: A V
authors.initials: AV
authors.lastname: Rudakova
authors.forename: E Z
authors.initials: EZ
authors.lastname: Yakupov
mesh_terms: D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use*; D002230:Carbidopa / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005060:Europe; D006801:Humans; D007980:Levodopa / Q000191:economics / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D002230:Carbidopa